BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9725052)

  • 1. [The in vitro combination-effect of toremifene with CAF (cyclophosphamide, adriamycin, 5-fluorouracil) on growth of various human mammary carcinomas].
    Kuroiwa S; Maruyama S; Okada M; Abe F
    Gan To Kagaku Ryoho; 1998 Aug; 25(10):1581-9. PubMed ID: 9725052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Combined effects of toremifene and paclitaxel on human breast cancer cell lines].
    Maruyama S; Kuroiwa S; Saimoto A; Nishikawa K
    Gan To Kagaku Ryoho; 2003 May; 30(5):669-75. PubMed ID: 12795099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Toremifene sensitized the effect of adriamycin on human breast cancer cell lines].
    Nakagomi H; Furuya K; Hagiwara J; Nishio T; Watanabe K; Muto S; Takano K; Tada Y
    Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():454-8. PubMed ID: 9589052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of different combinations of tamoxifen and toremifene on estrogen receptor-positive breast cancer cell lines.
    Coradini D; Biffi A; Cappelletti V; Di Fronzo G
    Cancer Detect Prev; 1995; 19(4):348-54. PubMed ID: 7553677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of breast cancer patient of CAF (cyclophosphamide, adriamycin, 5-fluorouracil) resistant lung metastasis with remarkable response to reverse drug-resistance by toremifene].
    Kusama M; Kaise H; Nakayama S; Ohta D; Aoki T; Koyanagi Y
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1171-5. PubMed ID: 10431584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance in chemotherapy for breast cancer.
    Saeki T; Tsuruo T; Sato W; Nishikawsa K
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Synergistic effect of toremifene and cisplatin on human lung cancer cell line A549].
    Zhang X; Li Q; Han Y; Liu Z
    Zhonghua Zhong Liu Za Zhi; 2002 Nov; 24(6):537-9. PubMed ID: 12667319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toremifene enhances cell cycle block and growth inhibition by vinblastine in multidrug resistant human breast cancer cells.
    Baker WJ; Maenpaa JU; Wurz GT; Koester SK; Seymour RC; Emshoff VD; Wiebe VJ; DeGregorio MW
    Oncol Res; 1993; 5(6-7):207-12. PubMed ID: 8123940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF; Green SJ; Ravdin PM; Lew D; Martino S; Abeloff M; Lyss AP; Allred C; Rivkin SE; Osborne CK
    J Clin Oncol; 2005 Nov; 23(33):8313-21. PubMed ID: 16293862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer.
    Saeki T; Nomizu T; Toi M; Ito Y; Noguchi S; Kobayashi T; Asaga T; Minami H; Yamamoto N; Aogi K; Ikeda T; Ohashi Y; Sato W; Tsuruo T
    J Clin Oncol; 2007 Feb; 25(4):411-7. PubMed ID: 17179098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
    Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
    Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
    Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Additive and synergistic effects of a novel antiestrogen, toremifene (Fc-1157a), and human interferons on estrogen responsive MCF-7 cells in vitro.
    Kangas L; Nieminen AL; Cantell K
    Med Biol; 1985; 63(4):187-90. PubMed ID: 2419713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator.
    McDougal A; Wormke M; Calvin J; Safe S
    Cancer Res; 2001 May; 61(10):3902-7. PubMed ID: 11358803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Status of estrogen receptor affects the drug sensitivity of drug-resistant MCF-7/Adr human breast cancer cells to droloxifene and Adriamycin].
    Gao HD; Sun JZ; Bi DS; Ma R
    Ai Zheng; 2003 Apr; 22(4):376-9. PubMed ID: 12703992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
    Yamamoto Y; Kawazoe T; Iwase H
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of medroxyprogesterone acetate on the anticellular activity of 5-fluorouracil against human breast and stomach cancer cells].
    Ishida H; Okabe M; Gomi K; Horiuchi R
    Gan To Kagaku Ryoho; 1993 Apr; 20(5):625-30. PubMed ID: 8470920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats.
    Yoshida M; Fujioka A; Nakano K; Kobunai T; Saito H; Toko T; Takeda S; Unemi N
    Anticancer Res; 1996; 16(3A):1155-9. PubMed ID: 8702227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells.
    Kurebayashi J; Nukatsuka M; Nagase H; Nomura T; Hirono M; Yamamoto Y; Sugimoto Y; Oka T; Sonoo H
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):515-25. PubMed ID: 16900372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.